- /
- Supported exchanges
- / US
- / CRL.NYSE
Charles River Laboratories (CRL NYSE) stock market data APIs
Charles River Laboratories Financial Data Overview
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Charles River Laboratories (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Charles River Laboratories data using free add-ons & libraries
Get Charles River Laboratories Fundamental Data
Charles River Laboratories Fundamental data includes:
- Net Revenue: 4 015 M
- EBITDA: 877 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-18
- EPS/Forecast: 2.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Charles River Laboratories News
New
3 Reasons CRL is Risky and 1 Stock to Buy Instead
Over the past six months, Charles River Laboratories has been a great trade, beating the S&P 500 by 7.5%. Its stock price has climbed to $168.91, representing a healthy 10.5% increase. This was partly...
Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit
SINGAPORE, March 12, 2026 /PRNewswire/ -- Locus Cell Co., Ltd. ("Locus Cell"), a Taiwan-based cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO), and Charles River ...
IQVIA Expands In Vitro Discovery Footprint As Shares Face Pressure
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. IQVIA Holdings (NYSE:IQV) has agreed to acquire discovery services assets from Charl...
Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
Quick Read Citi is positioning selectively across life sciences by favoring recovery names with clear catalysts while avoiding companies navigating accounting uncertainty, with Agilent’s pending Bi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.